Sanofi-Aventis to pay up to $560 million for single product TargeGen
This article was originally published in Scrip
Executive Summary
Sanofi-Aventis is to acquire the privately held US biopharmaceutical firm TargeGen for $75 million up front and additional milestone payments related to the development of its lead product, TG 101348, which could see the deal valued at a total of $560 million.
You may also be interested in...
Inrebic Approval Is A Boost For Myelofibrosis And Celgene's Buyer Bristol
Investors in Impact Biosciences, which sold the selective JAK2 inhibitor to Celgene for $1.1bn up front, could double their money with milestone fees based on fedratinib's approval.
Keeping Track: Accelerated Approval For Tecentriq And A Burst Of Filings And Submissions
The latest drug development news and highlights from our US FDA Performance Tracker.
Finance Watch: NDA-Ready Impact Gets Commitment For Another $90m
Start-up Impact's new structured financing – its second fundraising event this month – will pay out in increments as fedratinib nears the market. Also, Ablynx closed its $200m US IPO; Chi-Med follow-on brings in $262m; and VCs gives Cydan $34m to launch new companies.